Diagnostic immunohistochemistry in uterine sarcomas: A study of 397 cases

International Journal of Gynecological Pathology

Volumn 30, Issue 3, 2011, Pages 236-243

  Abeler, Vera M ^a   Nenodovic, Maja ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Department of Pathology   (Norway)

Author keywords

Differential diagnosis; Immunohistochemistry; Uterine sarcoma

Indexed keywords

ACTIN; CD103 ANTIGEN; CD31 ANTIGEN; CHLORDANE; CYTOKERATIN AE1; CYTOKERATIN AE3; DESMIN; PROTEIN S 100; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR; VIMENTIN;

ARTICLE; CANCER PATIENT; DIAGNOSTIC VALUE; FEMALE; GIANT CELL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHABDOMYOSARCOMA; UTERUS SARCOMA;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; SARCOMA; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 79955070831     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318200caff     Document Type: Article

References (23)

1. McCluggage WG. Immunohistochemical and functional biomarkers of value in female genital tract lesions. Int J Gynecol Pathol 2006;25:101-20. (Pubitemid 44620172)
2. Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med 2008;132:402-23. (Pubitemid 351337535)
3. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms: frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 2000;113:374-82. (Pubitemid 30217385)
4. Chu PG, Arber DA, Weiss LM, et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 2001;14:465-71. (Pubitemid 32448746)
5. Nucci MR, O'Connell JT, Huettner PC, et al. H-caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol 2001: 25;455-63. (Pubitemid 32240884)
6. Oliva E, Young R, Amin M, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002;26:403-12. (Pubitemid 34280112)
7. Soslow RA, Ali A, Oliva E. Mullerian adenosarcoma: an immunophenotypic analysis of 35 cases. Am J Surg Pathol 2008;32:1013-21.
8. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 2009;40:1571-85.
9. Carvalho JC, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroups. Cancer 2009;115:4186-95.
10. Abeler VM, Røyne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathologic and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355-64.
11. Dabbs D. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia: Churchill Livingstone; 2006;69-70.
12. Nicolas MM, Tamboli P, Gomez JA, et al. Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases. Hum Pathol 2010; 41:663-71.
13. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001;39:273-8. (Pubitemid 34279662)
14. Toki T, Shimizu M, Takagi Y, et al. CD10 is a marker for normal and neoplastic endometrial stromal cells. Int J Gynecol Pathol 2001;2001:41-7.
15. Hendrickson MR, Tavassoli FA, Kempson RL, et al. World Health Organization classification of tumours. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:236.
16. Simpson KW, Albores-Saavedra J. HMB-45 reactivity in conventional uterine leiomyosarcomas. Am J Surg Pathol 2007; 31:95-8. (Pubitemid 46036907)
17. Hurrell DP, McCluggage WG. Uterine leiomyosarcoma with HMB45+ clear cell areas: report of two cases. Histopathology 2005;47:534-48.
18. Silva EG, Deavers MT, Bodurka DC, et al. Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa. Am J Surg Pathol 2004;28:244-9. (Pubitemid 38124734)
19. Barcus RL, Williams TW, Gainey T, et al. HMB-45 immunoreactivity in uterine mesenchymal tumors (Abstract). Mod Pathol 2000;13:120A.
20. Vang R, Kempson R. Perivascular epithelioid cell tumor ("PEComa") of the uterus. A subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Am J Surg Pathol 2002;26:1-13. (Pubitemid 34019987)
21. Wang L, Felix JC, Lee JL, et al. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Oncol 2003;90:402-6. (Pubitemid 36952035)
22. Winter WE, Seidman JD, Krivak TC, et al. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol 2003;91:3-8. (Pubitemid 37188588)
23. Klein WM, Kurman RJ. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol 2003;22:181-4. (Pubitemid 36348793)